Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IIb study is designed to evaluate the the long-term efficacy, safety and immunogenicity of the 580299 HPV vaccine (CervarixTM) in a Brazilian cohort of women vaccinated in the phase IIb, blinded, primary study 580299/001 (NCT00689741) and having participated in follow-up study 580299/007 (NCT00120848). Only subjects who participated in the primary \& follow-up study will be enrolled in this long-term follow-up study. Subjects were aged 15-25 years at the time of entry into the primary study.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: qHPV Vaccine in Extension Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): qHPV Vaccine in Base Study, qHPV Vaccine in Extension Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, Procedure: Collection of cervical specimen, Biological: Cervarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, Procedure: Collection of cervical specimen | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group, Placebo Group | Intervention Type: PROCEDURE; Name: Collection of cervical specimen; Assigned to Arm(s): Cervarix Group, Placebo Group | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group
C: Arm Label: 3-dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2 doses by default; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Single-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Unvaccinated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®); Assigned to Arm(s): 2 doses by default, 2-dose, 3-dose, Single-dose
D: Arm Label: A: HAART naive or no HAART in past 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Arm Label: B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Intervention Type: BIOLOGICAL; Name: HPV vaccine for strains -6, -11, -16, and -18; Assigned to Arm(s): A: HAART naive or no HAART in past 6 months, B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months

Answer: B